← Back to Search

Local Anesthetic

Exparel for Pain

N/A
Waitlist Available
Led By Jason P. Rehm, MD
Research Sponsored by University of Tennessee
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up pre-op, post-op days: 1,2,3,4, and 14
Awards & highlights

Study Summary

The purpose of this study is to demonstrate improved pain control and outcomes in wrist operations with the use of a long-acting local anesthetic, EXPAREL, when compared to the use of the standard local anesthetic, Marcaine.

Eligible Conditions
  • Pain

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~pre-op, post-op days: 1,2,3,4, and 14
This trial's timeline: 3 weeks for screening, Varies for treatment, and pre-op, post-op days: 1,2,3,4, and 14 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Changes in Pain

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: ExparelExperimental Treatment1 Intervention
EXPAREL arm: one vial (266 mg/20 mL) of EXPAREL (Bupivicaine Extended-Release Liposome, 13.3mg/ml), undiluted, will be administered for each of the specified procedures.
Group II: ControlActive Control1 Intervention
15 cc of Marcaine 0.5% (Bupivacaine 0.5%, 5mg/ml) will be administered into the wrist per the Surgeon's Standard practice.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bupivacaine
FDA approved

Find a Location

Who is running the clinical trial?

University of TennesseeLead Sponsor
189 Previous Clinical Trials
141,959 Total Patients Enrolled
2 Trials studying Pain
59 Patients Enrolled for Pain
Jason P. Rehm, MDPrincipal InvestigatorUniversity of Tennessee College of Medicine Chattanooga

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~6 spots leftby Apr 2025